Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice

Irena Angelova‐Fischer; Franziska Adlbrecht; Wolfram Hötzenecker

doi:10.1007/s40629-026-00370-2

April 28, 2026Allergo Journal InternationalOpen Access

Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the long-term maintenance of disease control in patients with recalcitrant chronic eczema following dupilumab treatment de-escalation.
Seven patients with recalcitrant eczema received dupilumab treatment for at least one year.
Treatment was de-escalated while monitoring disease control and tolerance.
All seven patients maintained disease control for a minimum of one year after de-escalation.
Dupilumab demonstrated good tolerability throughout the treatment period.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Shows long-term disease control in chronic eczema patients after dupilumab treatment de-escalation, indicating effective maintenance strategies.

Abstract

ResultsDupilumab was well-tolerated and all seven patients remained on treatment for at least 1 year.The follow- KLong-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or. . .

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Angelova‐Fischer et al. (2026) studied this question.

synapsesocial.com/papers/69f593f271405d493affebed https://doi.org/10.1007/s40629-026-00370-2

View Full Paper

Ask AI

Bookmark

Share

Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Long-term maintenance of disease control in recalcitrant atopic and non-atopic chronic hand or hand-and-foot eczema after dupilumab treatment de-escalation in clinical practice

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading